Turalio Dosing Regimen Updated for Tenosynovial Giant Cell Tumor
A new dosing regimen for Turalio (pexidartinib) is available for the treatment of adults with symptomatic tenosynovial giant cell tumor.
A new dosing regimen for Turalio (pexidartinib) is available for the treatment of adults with symptomatic tenosynovial giant cell tumor.
The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
[Cancer Management and Research] A single-institution study that evaluated the efficacy and safety of apatinib, a specific TKI, in patients aged 16 years and older with advanced osteosarcoma progressing on chemotherapy showed that some AEs may be markers for improved PFS and clinical benefit rate.
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
This fact sheet reviews bone cancer, including its possible causes, frequency, symptoms, diagnosis, and treatment.
This phase 2 study sought to determine whether concurrent pantoprazole would improve cisplatin-induced ototoxicity and nephrotoxicity in younger patients with osteosarcoma.